This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

DermTech Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Bret Christensen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

CEO

Bret Christensen (52 yo)

less than a year

Tenure

Mr. Bret Christensen serves as Chief Executive Officer, President and Director at DermTech, Inc. since May 2023. He serves as Director of Axena Health, Inc. Mr. Christensen had been Chief Commercial Office...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Sun	CFO, Treasurer & Secretary	4.1yrs	US$1.46m	0.42% MX$ 4.0m
Claudia Ibarra	Chief Operating Officer	4yrs	US$1.20m	0.25% MX$ 2.3m
Ray Akhavan	General Counsel	2.8yrs	US$1.20m	0.12% MX$ 1.2m
Bret Christensen	President	less than a year	geen gegevens	geen gegevens
William Zondler	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Steve Kunszabo	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Jennifer Eilemberg	Chief Compliance Officer	1.3yrs	geen gegevens	geen gegevens
Ray Bassi	Vice President of Sales	2.3yrs	geen gegevens	geen gegevens
Burkhard Jansen	Chief Medical Affairs Officer	6.8yrs	US$480.83k	geen gegevens
Daniel Visage	Senior Vice President of Payer Access	4.8yrs	geen gegevens	geen gegevens
Loren Clarke	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens
Steven Stone	Senior Vice President of Research & Development	1.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: DMTK *'s management team is considered experienced (2.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bret Christensen	President	less than a year	geen gegevens	geen gegevens
Herman Rosenman	Independent Director	4.2yrs	US$239.85k	0.29% MX$ 2.8m
Kirk Malloy	Independent Director	1.3yrs	US$312.01k	0.013% MX$ 123.4k
Matthew Posard	Independent Chairman of the Board	7.3yrs	US$272.18k	0.36% MX$ 3.4m
Mark Capone	Independent Director	1.3yrs	US$312.43k	0.059% MX$ 556.2k
Cynthia Collins	Independent Director	4.2yrs	US$240.18k	0.21% MX$ 1.9m
Nathalie Keraudy	Independent Director	2yrs	US$217.05k	0.092% MX$ 867.6k

2.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: DMTK *'s board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

This company listing is no longer active

DermTech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces Change of CEO

DermTech, Inc. Announces Board Committee Appointments

Chief Operating Officer recently sold Mex$292k worth of stock

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Motion for Joint Administration Approved for DermTech, Inc.

DermTech, Inc. Filed for Bankruptcy

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

DermTech, Inc. Announces Change of CEO

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

DermTech, Inc. Announces Board Committee Appointments

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Chief Operating Officer recently sold Mex$292k worth of stock

High number of new directors

Second quarter 2022 earnings released: US$0.99 loss per share (vs US$0.59 loss in 2Q 2021)

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

High number of new and inexperienced directors

Dermtech Announces New Board Appointment

High number of new and inexperienced directors

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech, Inc. announced delayed annual 10-K filing

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new and inexperienced directors

DermTech, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new and inexperienced directors

President recently sold Mex$687k worth of stock

Chief Operating Officer recently sold Mex$1.3m worth of stock

High number of new and inexperienced directors

DermTech Unveils DermTech Stratum

Third quarter 2021 earnings released: US$0.68 loss per share (vs US$0.50 loss in 3Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$3.1m worth of stock

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.58 loss in 2Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$2.5m worth of stock

President recently sold Mex$7.6m worth of stock

Dermtech, Inc. Provides Earnings Results for the Second Quarter of 2021

DermTech, Inc. Provides No Financial Guidance for the Fiscal Year 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd